Corcept Therapeutics (CORT) Stock Price, Quote & News

Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also develop...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 327 3270

Website: www.corcept.com

Address:

101 Redwood Shores Parkway, Redwood City, United States

gucag006 Jun. 25 at 5:47 AM

$CORT Making another shot at $80. The current SP is supported by Korlym. Adding relacorilant towards the end of the year, it should support SP ranging from $120 to $150. Relacorilant for ovarian cancer next year should push SP towards $200. Then comes dazucorilant for ALS in 2027 and beyond. Folks, as one of the three main hormonal therapies, gliflizin, GLP-1 and corilant, its potential matches the other two, which has racked in 100s of $B in profits for almost all major BPs. Corcept will join them too soon, i.e., MC values for 100s of $BS.

0 · Reply

OX50 Jun. 24 at 8:02 PM

$CORT Analysts have CORT's target price at $138.00. I have it at $150.

0 · Reply

OX50 Jun. 24 at 7:11 PM

$CORT LSEG Reiterated since 09/24/2019 Strong Buy LSEG Stocks Plus Report Latest Report 06/24/2025 LSEG maintains a current price target of $138.25 for CORT

0 · Reply

Thestocktraderhubzee Jun. 24 at 10:39 AM

WATCHLIST JUN 24 2025 $CORT Corcept Therapeutics Reveals That Catalyst Trial Meets Primary Endpoint With Improvement In HbA1c; Catalyst Trial Meets Secondary Endpoints With Reduced Body Weight And Waist Circumference $SAM SmartStop Self Storage REIT Announces The Acquisition Of A Class A Self-Storage Facility In Houston, Texas; No Terms Disclosed $KLTO Klotho Neuroscience Partners With Okinawa Longevity Experts to Explore Gene Therapy for Healthy Aging $LGVN Longeveron Completes Enrollment Of Phase 2b Clinical Trial Evaluating Investigational Cellular Therapy Laromestrocel As Potential Adjunct Treatment For Hypoplastic Left Heart Syndrome $VZ Verizon Unveils AI-Powered Customer Experience Overhaul Built On America's Fastest, Most Reliable 5G Network

0 · Reply

HericuleParrot Jun. 24 at 7:38 AM

$CORT may cross 86 soon

0 · Reply

BigSqueezeComing Jun. 24 at 3:55 AM

$CORT https://www.businesswire.com/news/home/20250623903022/en/Corcept-Presents-Data-from-Treatment-Phase-of-CATALYST-Trial-at-American-Diabetes-Associations-85th-Scientific-Sessions-with-Simultaneous-Publication-in-Diabetes-Care

0 · Reply

DylanGFM Jun. 24 at 3:44 AM

$CORT LOOKS LIKE IT WAS A DECENT LONG TERM INVESTMENT

1 · Reply

BalaBioResearch Jun. 24 at 1:13 AM

$CORT I recommend all who are interested/invested in Corcept $CORT to look at their ADA presentations from today. The presented CATALYST study data is transformational for the diabetes field and any endo who sees the data will change how they treat patients. A stat sig decrease in A1c for such a heavily pretreated population is a massive benefit as well as stat sig weight loss and other health benefits. This readout is what I (and probably management) is expecting to cause the acceleration in revenue growth necessary to hit guidance. Korlym has many safety problems and I'm assuming when relacorilant launches there will be an influx of women who were hesitant to take Korlym who start on relacorilant quite quickly. Also a fun note, in my report a few weeks ago I predicted a diabetes based TAM of 1.17m people and their presentation today cited 1.125m people. GLTA

0 · Reply

DonCorleone77 Jun. 23 at 8:39 PM

$CORT Corcept says Catalyst trial met primary endpoint Corcept Therapeutics Incorporated presented data from the randomized, double-blind, placebo-controlled treatment phase of its CATALYST trial of Korlym in patients with hypercortisolism and difficult-to-control type 2 diabetes at the American Diabetes Association's 85th Scientific Sessions. CATALYST met its primary endpoint. Patients who received Korlym exhibited a clinically meaningful and statistically significant improvement in hemoglobin A1c, which decreased 1.47 percent from baseline, compared to a 0.15 percent decrease in patients who received placebo. Of the 91 patients in the treatment group, 65received at least 600mg of Korlym and 28 received 900mg. Patients who received 900mg of Korlym had an improvement in HbA1c of 2.01 percent, compared to a 0.16 percent decrease in patients who received placebo. The trial also met its secondary endpoints, as patients who received Korlym exhibited significantly reduced body weight and waist circumference, compared to patients who received placebo. Patients receiving Korlym achieved these improvements despite reducing or discontinuing their glucose-lowering medications. Adverse events in CATALYST were manageable and consistent with Korlym's known safety profile. The most common adverse events were hypokalemia, fatigue and nausea.

0 · Reply

HericuleParrot Jun. 20 at 2:38 PM

$CAVA $CORT When rules of game is known,one simply buy and hold

0 · Reply

Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association's 85th Scientific Sessions with Simultaneous Publication in Diabetes Care

Jun 13, 2025, 5:37 PM EDT - 11 days ago

Corcept: Remains A Strong Buy On Recent Weakness And Aggressive Sales Force Hiring

Jun 11, 2025, 7:00 AM EDT - 13 days ago

20 stocks you should avoid — no matter how well the market does

CPRX CRK CRNC DDD LUMN LYV MGPI

Jun 5, 2025, 6:00 AM EDT - 20 days ago

Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting

Jun 2, 2025, 11:15 AM EDT - 22 days ago

Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

May 5, 2025, 8:34 PM EDT - 7 weeks ago

Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript

May 5, 2025, 4:05 PM EDT - 7 weeks ago

CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Apr 28, 2025, 4:05 PM EDT - 2 months ago

CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL

Apr 23, 2025, 11:30 AM EDT - 2 months ago

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025

Apr 22, 2025, 5:23 PM EDT - 2 months ago

Corcept: Maintaining Strong Buy Even After 4Q Revenue And Earnings Miss

Apr 21, 2025, 8:00 AM EDT - 2 months ago

Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes

Apr 15, 2025, 4:00 PM EDT - 2 months ago

It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder

Apr 7, 2025, 8:00 AM EDT - 2 months ago

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer

Apr 1, 2025, 1:43 PM EDT - 3 months ago

Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release

Apr 1, 2025, 7:15 AM EDT - 3 months ago

Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company

Mar 31, 2025, 3:01 PM EDT - 3 months ago

Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast

Mar 31, 2025, 8:18 AM EDT - 3 months ago

Corcept's ovarian cancer combination drug meets main goal in late-stage study

Mar 31, 2025, 8:00 AM EDT - 3 months ago

Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Mar 12, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Bronstein, Gewirtz & Grossman, LLC (CORT) Investors to Inquire about Securities Investigation

Mar 11, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Shareholders to Inquire about Securities Investigation

Mar 10, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Shareholders to Connect

Mar 10, 2025, 8:00 AM EDT - 3 months ago

Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

Mar 9, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Corcept Therapeutics Incorporated (CORT) And Encourages Shareholders to Reach Out

Mar 7, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Shareholders to Learn More About the Investigation

Mar 6, 2025, 10:00 AM EST - 3 months ago

Corcept Therapeutics Incorporated (CORT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Mar 5, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Investors to Connect

Mar 4, 2025, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Stockholders to Inquire about Securities Investigation

Mar 4, 2025, 7:03 AM EST - 4 months ago

Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025

GILD PRVA TGTX TKO

Mar 3, 2025, 4:05 PM EST - 4 months ago

FDA Files Corcept's New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

Mar 3, 2025, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Investors to Learn More About the Investigation

Mar 2, 2025, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Stockholders to Learn More About the Investigation

Feb 28, 2025, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Investors to Inquire about Securities Investigation

Feb 27, 2025, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Corcept Therapeutics Incorporated (CORT) And Encourages Investors to Reach Out

Feb 26, 2025, 9:53 PM EST - 4 months ago

Corcept Therapeutics, Inc. (CORT) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 4 months ago

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update

Feb 26, 2025, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Corcept Therapeutics Incorporated (CORT) And Encourages Stockholders to Reach Out

Feb 25, 2025, 10:30 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Stockholders to Connect

Feb 12, 2025, 4:05 PM EST - 4 months ago

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call

Jan 29, 2025, 7:37 AM EST - 5 months ago

Big Money Keeps Buying Corcept

Jan 24, 2025, 11:00 AM EST - 5 months ago

Kuehn Law Encourages Investors of Corcept Therapeutics Inc. to Contact Law Firm

gucag006 Jun. 25 at 5:47 AM

0 · Reply

OX50 Jun. 24 at 8:02 PM

$CORT Analysts have CORT's target price at $138.00. I have it at $150.

0 · Reply

OX50 Jun. 24 at 7:11 PM

$CORT LSEG Reiterated since 09/24/2019 Strong Buy LSEG Stocks Plus Report Latest Report 06/24/2025 LSEG maintains a current price target of $138.25 for CORT

0 · Reply

Thestocktraderhubzee Jun. 24 at 10:39 AM

0 · Reply

HericuleParrot Jun. 24 at 7:38 AM

$CORT may cross 86 soon

0 · Reply

BigSqueezeComing Jun. 24 at 3:55 AM

0 · Reply

DylanGFM Jun. 24 at 3:44 AM

$CORT LOOKS LIKE IT WAS A DECENT LONG TERM INVESTMENT

1 · Reply

BalaBioResearch Jun. 24 at 1:13 AM

0 · Reply

DonCorleone77 Jun. 23 at 8:39 PM

0 · Reply

HericuleParrot Jun. 20 at 2:38 PM

$CAVA $CORT When rules of game is known,one simply buy and hold

0 · Reply

HericuleParrot Jun. 16 at 3:20 PM

$CORT this is stuck at 70 now no option left except to gap up on some good news. Any potential news coming our way

1 · Reply

Gps_100X_ROI_Potential Jun. 14 at 6:45 PM

$SLS wanted to Clarify: Gps Achieved A Statistically Significant 21 month Median OS in the AML Cr2 Phase 2. - the IDMC Unblinded - ALL POOLED Phase 3 OS Data. - ALL Pooled P3 Patient Median OS, Not Yet Met, and >Greater than 13.5 Months - 13.5 months for Control Patients on BAT and GPS Arms Combined. - Current SOC with Best Available Treatments (BAT) is just 6-8 months, according to 3 Dr's Treating Actual P3 patients, as well as multiple other published Trials, including the below: Median OS of 8.82 Months on BAT for AML CR2 Remission Patients - NOT GETTING TRANSPLANT - ie the SLS P3 SETTING AML CR2 NON TRANSPLANT. -- NOTE: with Gps P3 Patient OS at 21 +/- months / control OS would Be in the 8 month Range - the MATH STACKS UP $IMGN $CORT $MRTX

1 · Reply

Gps_100X_ROI_Potential Jun. 14 at 12:47 AM

$SLS $165M will instantly be worth Multiple Billions. FDA REGISTRATIONAL Phase 3 Trial Result, a Massive Catalyst that will Give Gps Immunotherapy the FDA Green Light to a $6B TAM - which is worth $10B+ to Big Pharma - will be Announced ANY DAY NOW Current Cash runway into Q3, 2026, $32.4M on hand $5.8M Q/burn... Also, $3DMED will be begging to Pay the $63M from the $202M License, they'll Owe SLS THIS YEAR. They finally have the Money AND Will Pay to Retain their China rights. GPS has FDA Orphan and Fast Track - on the RTOR, already has FDA Type C manufacture BLA sign off... its only 6 months to Gen Revenue, not that SLS will be doing it, BIG PHARMA WILL BE BUYING SLS FOR $14B + well before hand. $CORT $IMGN $ABBV $MRK

0 · Reply

HericuleParrot Jun. 13 at 11:53 AM

$CORT 4 shares traded ,they can not cow it down, 86 breakout will come by soon very soon.

0 · Reply

Gps_100X_ROI_Potential Jun. 13 at 4:17 AM

$SLS The next PR we See about GPs will be Something like the $CORT Phase 3 PR --- which added $7B in Market Value in a Single Day. $CORT Relacorilant + Chemo achieved a 16 month Median OS for Plat Resistant Ovarian Cancer Patients -- and the share Price Launched. Similarly $IMGN Elahere was a $270M Mcap when it achieved a 16.46 Month P3 Result in the Same Setting - $ABBV Bought IMGN for $10.1B Months Later. Interestingly, Gps +Keytruda $MRK achieved a MOS of 18.4 months in the same Exact PROC Setting. SLS MCAP 165M - Massive Value Staring Right at You. GPS Phase 3 Results for AML Remission Maintenance Will Be Announced ANY DAY NOW.

0 · Reply

Gps_100X_ROI_Potential Jun. 12 at 7:52 PM

$SLS Keep in Mind GPS +Keytruda $MRK OS of 18.4 months in in Platinum Resistant Ovarian Cancer, is better than $CORT which added $7B the day its p3 was and announced, and better than Elahere, 16.46 months, $IMGN which got bought by $ABBV for $10.1B.

0 · Reply

druvaciam Jun. 12 at 6:48 PM

$CORT Below $70 again...

0 · Reply

Gps_100X_ROI_Potential Jun. 11 at 10:50 PM

$SLS PSA @CEA is a S--Mbag Liar ... says the company guided for Sept Final Analysis - which is total S__t and he cites the NCT dates... which is only ever been Placeholder for all trias. As an EXAMPLE -- $CORT P3 Results Came in March 31 2025, even though the Clinicaltrial.gov Primary Completion was Estimated 2026-03 -- Primary Endpoint Met in Corcept's Pivotal Phase 3 ... Corcept Therapeutics https://ir.corcept.com › news-release-details › primary-e... Mar 31, 2025 — In ROSELLA, patients treated with relacorilant in addition to nab-paclitaxel chemotherapy experienced a 30 percent reduction in risk of disease ... https://clinicaltrials.gov/study/NCT05257408?term=relacorilant&rank=6 $THOMPSKE @MZJ1979 @FatherofTrades @JDT72 @Gnomicidal69 link to several of @cea 's lies like when he lied about the idmc unblinding actual p3 data, he says they didn't - he lied about hkiac judges and enrollment timelines too... -- HE HAS SOLD COVERD CALLS SC--BAG LIAR. https://stocktwits.com/Gps_100X_ROI_Potential/message/617595133 @BARITONE1 @SINOR1 @LONGNSTRONGDONG @JUSTJINVESTING @DolomiteMike

0 · Reply

Gps_100X_ROI_Potential Jun. 11 at 7:23 PM

$SLS $IMGN $CORT $MRTX

1 · Reply

HericuleParrot Jun. 10 at 2:45 PM

$CORT future is extremely bright so i hold

0 · Reply

Daniech0514 Jun. 9 at 8:51 PM

$CORT looks like they are presenting Catylyst data June 23rd at ADA. Not likely to be a moving event but it's great that they get there data out there.

1 · Reply

RogerRipper Jun. 9 at 4:15 PM

$CORT Pinned at max pain of $70 already?

0 · Reply

Market Cap	7.88B
Revenue (ttm)	675.04M
Net Income (ttm)	141.21M
EPS (ttm)	N/A
PE Ratio	61.53
Forward PE	51.26
Profit Margin	20.92%
Debt to Equity Ratio	0.00

Volume	889,000
Avg Vol	1,326,254
Day's Range	N/A - N/A
Shares Out	106.05M
Stochastic %K	92%
Beta	0.19
Analysts	Strong Sell
Price Target	$138.25